Showing 1591-1600 of 3545 results for "".
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an
- Evolus Acquires Exclusive US Distributor Rights to Evolysse Line of Dermal Fillershttps://practicaldermatology.com/news/evolus-acquires-exclusive-us-distributor-rights-to-evolysse-line-of-dermal-fillers/2461710/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang
- AI In Action: Rubedo Life Sciences Introduces RLS-1496 as a Potential First-in-Class Derm Drughttps://practicaldermatology.com/news/ai-in-action-rubedo-life-sciences-introduces-rls-1496-as-a-potential-first-in-class-derm-drug/2461699/Rubedo Life Sciences has nominated RL
- Study: Atopic Asthma/Eczema Linked to Heightened Risk of Osteoarthritishttps://practicaldermatology.com/news/study-atopic-asthmaeczema-linked-to-heightened-risk-of-osteoarthritis/2461635/People with atopic diseases like asthma or eczema may be at heightened risk of osteoarthritis, according to research published online in the Annals of the Rheumatic Diseases. Drugs used to dampen d
- Iovance Biotherapeutics Completes Biologics License Application Submission for Lifileucel in Advanced Melanomahttps://practicaldermatology.com/news/iovance-biotherapeutics-completes-biologics-license-application-submission-for-lifileucel-in-advanced-melanoma/2461633/Iovance Biotherapeutics announced it has completed its rolling Biologics License Application (BLA) submission to the FDA for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced (unresectable or metastatic) melanoma w
- Novel Rare Mutation in ABCA12 Gene linked to HIhttps://practicaldermatology.com/news/novel-rare-mutation-in-abca12-gene-linked-to-hi/2461600/A novel rare skin mutation in ABCA12 gene is linked to Harlequin Ichthyosis, according to a new case study published in Frontiers in Pediatrics. Harlequin ichthyosis (HI) is a severe genetic skin disorder characterized by thick white, brown, or dark b
- Ribon Therapeutics: First Patient Dosed in Phase 1 Study with RBN-3143 of ADhttps://practicaldermatology.com/news/ribon-therapeutics-first-patient-dosed-in-phase-1-study-with-rbn-3143-of-ad/2461599/Ribon Therapeutics dosed the first patient with RBN-3143 in the open-label cohort of patients with moderate-to-severe atopic dermatitis. The study aims to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in
- Candela Announces Health Canada Licences for Nordlys Multi-Application System and Frax Pro Devicehttps://practicaldermatology.com/news/candela-announces-health-canada-licences-for-nordlys-multi-application-system-and-frax-pro-device/2461586/Candela announced Health Canada licensing and the availability of the Nordlys multi-application platform, which features Selective Waveband Technology (SWT) and the dual-wavelength Frax Pro non-ablative fractional laser platform.[1-4] The Nordlys is designed to improve treatme
- Celluma Light Therapy Headquarters Moves to Tustin, Californiahttps://practicaldermatology.com/news/celluma-light-therapy-headquarters-moves-to-tustin-calif/2461570/BioPhotas, Inc., the maker of the Celluma Series of light therapy devices, is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, Calif. The new headquarters boasts 25,000 square feet of office and warehouse space, facilitating continued gro